OREANDA-NEWS. Actelion Ltd (SIX: ATLN) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Business Report of the year ending 31 December 2015 will be held on 4 May 2016 at 10.00 CEST at the Congress Center, Messe Basel, Switzerland.

At this year's meeting the Board of Directors is proposing a dividend payment of CHF 1.50 per share, an increase of 15%. The Board is also proposing the reduction of share capital by cancelation of shares repurchased on a second trading line as part of the company's share repurchase program of up to 10 million shares, initiated on 9 April 2015. Also, the Board is proposing the approval of a maximum compensation for the non-executive members of the Board of Directors and the maximum compensation amount for the Actelion Executive Committee.

The invitation was published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) on 6 April 2016 and is available, together with the Company's Annual Report and Compensation Report, on www.actelion.com/agm.

In order to attend and vote at the Annual General Meeting of Shareholders, Shareholders must have been registered in the Company's shareholder register by 22 April 2016 at the latest.


Actelion Ltd.
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.